Core Viewpoint - The article discusses ongoing legal issues faced by uniQure N.V. related to a securities class action lawsuit, highlighting significant criticisms from FDA officials regarding the company's gene therapy candidate AMT-130 and its clinical study practices [1][3][5]. Group 1: Legal Proceedings - A securities class action lawsuit has been filed against uniQure, representing investors who acquired shares between September 24, 2025, and October 31, 2025 [1][6]. - The deadline for investors to apply as Lead Plaintiff in the pending class action is April 13, 2026 [1][6]. Group 2: FDA Criticism - An FDA official labeled uniQure's AMT-130 as a "failed therapy," accusing the company of presenting a "distorted or manipulated comparison" in its clinical studies [3][7]. - The FDA has not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130, indicating a lack of regulatory consensus [8]. Group 3: Allegations Against uniQure - The lawsuit alleges that uniQure misrepresented its interactions with the FDA and failed to disclose critical information regarding the approval of its pivotal study design [5][6]. - Allegations include mischaracterization of sham surgeries, denial of prior agreements with the FDA, and misleading investors about the timeline for a Biologics License Application (BLA), which resulted in a 49% stock drop after the lack of FDA agreement was revealed [7][8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 7, 2026 [3]. - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that defendants made false and misleading statements regarding Inovio's CELLECTRA device manufacturing deficiencies [5]. - It is claimed that Inovio was unlikely to submit the INO-3107 Biologics License Application to the FDA by the second half of 2024 due to insufficient information [5]. - The lawsuit asserts that the overall regulatory and commercial prospects of INO-3107 were overstated, leading to material misstatements by the defendants [5].

Core Viewpoint - A securities class action lawsuit has been filed against Aldeyra Therapeutics, Inc. for failing to disclose critical information regarding clinical trial results, leading to significant stock price decline and investor harm [1][2][3]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the District of Massachusetts on behalf of all individuals or entities that purchased Aldeyra securities between November 3, 2023, and March 16, 2026 [1]. - The complaint alleges that the defendants did not disclose that the results of the reproxalap clinical trials were inconsistent, rendering any positive findings unreliable [2]. Group 2: Impact on Stock Price - Following the revelation of the alleged failures to disclose, Aldeyra's stock price fell by $2.99, approximately 70.7%, closing at $1.24 per share on March 17, 2026 [3]. Group 3: Investor Actions - Investors who acquired shares of Aldeyra are encouraged to contact the law firm before the lead plaintiff motion deadline on May 29, 2026, to discuss their rights and interests regarding the class action [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Picard Medical, Inc. regarding a securities class action lawsuit, highlighting allegations of fraudulent activities and misleading statements made by the company during a specified class period [1][2]. Group 1: Allegations - The lawsuit alleges that during the class period from September 2, 2025, to October 31, 2025, Picard Medical was involved in a fraudulent stock promotion scheme that included misinformation spread via social media and impersonation of financial professionals [2]. - It is claimed that insiders and affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [2]. - The company's public statements and risk disclosures allegedly omitted critical information regarding false rumors and artificial trading activity that influenced the stock price [2]. - As a result of these actions, the positive statements made by the defendants about the company's business and prospects were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Class Action Details - The deadline for shareholders to register for the class action lawsuit is April 3, 2026, and registration is encouraged to ensure participation in any potential recovery [3]. - Shareholders who register will be enrolled in a portfolio monitoring system to receive updates on the case's progress [3]. - There is no cost or obligation for shareholders to participate in the lawsuit [3]. Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered losses due to deceit, fraud, and illegal business practices [4]. - The firm aims to ensure that companies adhere to responsible business practices and engage in good corporate citizenship [4]. - The firm seeks recovery for investors affected by misleading statements or omissions that led to artificial inflation of stock prices [4].

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit against Snowflake Inc. (NYSE: SNOW) for allegedly issuing materially false and misleading statements during the class period from June 27, 2023, to February 28, 2024, which may have led to investor losses [2][4]. Group 1: Allegations and Impact - The lawsuit claims that Snowflake's management failed to disclose that product efficiency gains, specifically related to Iceberg Tables and tiered storage pricing, were expected to negatively impact consumption and revenues [2]. - As a result of these undisclosed factors, the positive statements made by the defendants regarding consumption patterns, revenues, and demand for Snowflake products were deemed to lack a reasonable basis [2]. Group 2: Class Action Details - Shareholders who purchased shares of SNOW during the specified class period are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for April 27, 2026 [3]. - Participants in the class action will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle, with no cost or obligation to participate [3].

Core Viewpoint - Coty Inc. is facing a securities class action lawsuit due to allegations of misleading statements regarding its financial performance and growth in the beauty market, particularly in the Consumer Beauty segment [2]. Summary by Sections Allegations - The lawsuit claims that Coty provided overly positive statements while concealing material adverse facts about its slowing growth, particularly in the Consumer Beauty market, which was underperforming [2]. - The company reported compressed margins due to increased marketing investments and a slowdown in its Prestige fragrance segment [2]. Financial Results - On February 4 and 5, 2026, Coty announced disappointing financial results for Q2 of fiscal year 2026, revealing worsening performance in the Consumer Beauty segment [2]. - Following the announcement, Coty withdrew its fiscal year 2026 guidance for EBITDA and revised its near-term outlook downward, attributing these changes to macroeconomic factors, rising costs, and a lack of operational discipline [2]. Stock Price Impact - After the announcement of the financial results, Coty's stock price fell from $3.43 per share on February 4, 2026, to $2.66 per share on February 6, 2026, marking a decline of approximately 22% [2]. Class Action Participation - Shareholders who purchased shares during the class period from November 5, 2025, to February 4, 2026, are encouraged to register for participation in the class action lawsuit, with a deadline for lead plaintiff applications set for May 22, 2026 [3].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Lufax Holding Ltd, alleging misrepresentations regarding the company's internal controls, which led to materially misstated financial results [4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased or acquired Lufax securities between April 7, 2023, and January 26, 2025 [1]. - Investors wishing to serve as lead plaintiff must file papers by May 20, 2026, and representation is on a contingency fee basis, meaning shareholders pay no fees or expenses [3]. Group 2: Company Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since its inception in 1993 and has a strong track record in class action litigation [5].

Group 1 - A class action lawsuit has been announced by Rosen Law Firm on behalf of purchasers of Coty Inc. common stock between November 5, 2025, and February 4, 2026 [1] - Investors who purchased Coty common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - The lawsuit alleges that Coty made false and misleading statements regarding its slowing growth in the beauty market, particularly in the Consumer Beauty segment and Prestige fragrance segment [5] Group 2 - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4] - The firm has been recognized for its success in securities class action settlements, being ranked No. 1 by ISS Securities Class Action Services in 2017 and consistently in the top 4 since 2013 [4] - Investors are encouraged to select qualified counsel with a proven history in leadership roles within securities litigation [4]

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Aldeyra Therapeutics, Inc. securities, alleging misleading statements regarding the company's drug candidate, reproxalap, during the Class Period from November 3, 2023, to March 16, 2026 [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Aldeyra's defendants made false and misleading statements about the clinical trial results of reproxalap, which were inconsistent and rendered positive findings unreliable [5]. - Investors who purchased Aldeyra securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the Aldeyra class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must move the Court by May 29, 2026, to represent other class members in the litigation [3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its leadership in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Atara Biotherapeutics, Inc. securities, alleging that the company made false and misleading statements regarding its regulatory prospects and manufacturing issues during the Class Period from May 20, 2024, to January 9, 2026 [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Atara Biotherapeutics failed to disclose significant manufacturing issues and deficiencies in the ALLELE study, which made FDA approval of the tabelecleucel Biologics License Application unlikely [5]. - The lawsuit asserts that these undisclosed issues heightened regulatory scrutiny risks and jeopardized ongoing clinical trials, negatively impacting Atara's business and financial condition [5]. - Investors are encouraged to join the class action, with no out-of-pocket fees or costs due to a contingency fee arrangement [2][3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 [4]. - Investors can join the class action by submitting a form or contacting the firm directly for more information [3][6].